HomeCompareFINE vs PFE

FINE vs PFE: Dividend Comparison 2026

FINE yields 0.98% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $30.0K in total portfolio value· pulled ahead in Year 9
10 years
FINE
FINE
● Live price
0.98%
Share price
$22.02
Annual div
$0.22
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.1K
Annual income
$104.19
Full FINE calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — FINE vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFINEPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FINE + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FINE pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FINE
Annual income on $10K today (after 15% tax)
$83.11/yr
After 10yr DRIP, annual income (after tax)
$88.56/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $23,040.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FINE + PFE for your $10,000?

FINE: 50%PFE: 50%
100% PFE50/50100% FINE
Portfolio after 10yr
$36.1K
Annual income
$13,657.37/yr
Blended yield
37.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

FINE
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FINE buys
0
PFE buys
0
No recent congressional trades found for FINE or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFINEPFE
Forward yield0.98%6.20%
Annual dividend / share$0.22$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$21.1K$51.1K
Annual income after 10y$104.19$27,210.54
Total dividends collected$1.0K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FINE vs PFE ($10,000, DRIP)

YearFINE PortfolioFINE Income/yrPFE PortfolioPFE Income/yrGap
1$10,798$97.78$9,161$701.38+$1.6KFINE
2$11,652$98.68$8,610$859.79+$3.0KFINE
3$12,567$99.52$8,366$1,081.25+$4.2KFINE
4$13,548$100.31$8,483$1,405.66+$5.1KFINE
5$14,597$101.06$9,084$1,907.24+$5.5KFINE
6$15,720$101.77$10,418$2,732.78+$5.3KFINE
7$16,923$102.43$13,007$4,193.56+$3.9KFINE
8$18,211$103.05$18,010$7,005.87+$201.00FINE
9← crossover$19,589$103.64$28,216$12,979.89$8.6KPFE
10$21,065$104.19$51,081$27,210.54$30.0KPFE

FINE vs PFE: Complete Analysis 2026

FINEStock

FINE aims to replicate an index of European companies generating at least 50% of their revenues from luxury-related business operations. The index is focused on companies headquartered in developed Europe, such as Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, or the United Kingdom. Eligible securities must meet certain size and trading volume requirements. After this basic screen, a proprietary natural language processing algo screens publicly available information such as financial news and business profiles to identify and score companies involved in the investment theme. These may include firms involved in the design, manufacturing, or sale of luxury and designer accessories, high-end or designer clothing and beauty products, exclusive and luxurious automobiles and boats, luxury hotels, resorts, and spas. The 25 highest ranking companies are included in the index and are given an equal weighting. The index is reconstituted annually and rebalanced semi-annually.

Full FINE Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this FINE vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FINE vs SCHDFINE vs JEPIFINE vs OFINE vs KOFINE vs MAINFINE vs JNJFINE vs MRKFINE vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.